A random comparative trial of 0.25, 0.5 and 1.0 g ceftazidime twice daily in urinary tract infection.
One hundred and sixty-six patients with complicated and uncomplicated urinary tract infections were randomized to therapy with either 0.25, 0.50 or 1.00 g of ceftazidime im or iv twice daily for five days. Bacteriological data were complete in 138 patients. Escherichia coli caused 50% of all infections, Klebsiella and Enterobacter spp. caused 10.9%, Pseudomonas spp caused 10.9%, Proteus spp. caused 10.7%, and 8.7% were caused by other Gram-negative bacteria. Staphylococcus and Streptococcus spp. caused 9.4%. Cure rate was lowest in infections caused by Pseudomonas (53.3%) and Proteus spp. (64.3%); however, most of these infections were complicated. No significant dose-related difference in efficacy was observed, but the 0.25 g dose had the lowest cure rate in each category. Nausea was the only side effect. The most common laboratory abnormalities were elevated liver function tests. Minimal changes in haematological and renal function were seen.
D000328:Adult; D000368:Aged; D002442:Ceftazidime; D002511:Cephalosporins / Q000008:administration & dosage* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008111:Liver Function Tests; D008297:Male; D008875:Middle Aged; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011897:Random Allocation; D013203:Staphylococcal Infections / Q000188:drug therapy; D013290:Streptococcal Infections / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy*
D002511:Cephalosporins; D002442:Ceftazidime